New-ATE-Logo2019 (1)

 

Improving Gene Therapy Viral

Vector Manufacturing Economics:

Modelling Bioprocess Costs

Presenters:

Emmanuelle Cameau
Strategic Technology Partnership Leader, Cell and Gene Therapy,
Pall Corporation
 
Emmanuelle has more than 14 years of experience in biotechnology process development and GMP production. Highly skilled in the field of cell culture applications, Emmanuelle joined Pall Biotech almost 10 years ago as a Bioprocess Specialist (BPS) during her first four years. She then transitioned to the Bioreactor Applications Team, where she was Principal Bioreactor Specialist until March 2021 when she joined the newly formed Gene Therapy Business Unit as Strategic Technology Partnership Leader. Prior to Pall, Emmanuelle worked as Biotech Process Sciences Upstream Process Development Engineer at Merck Serono for four years. She received her degree in biotechnology engineering from the former Ecole Supérieure d’Ingénieurs de Luminy (now Polytech Marseille). Emmanuelle is a keen horse rider and enjoys competing in horse jumping competitions.
 
Maxime Dumont
Cell & Gene Therapy Product Manager,
Polyplus-transfection

Maxime Dumont is the Cell and Gene Therapy Product Manager at Polyplus-transfection®. With two master’s degrees in biochemistry, project management and marketing of pharmaceutical products, Maxime has managed the CGT transfection reagent portfolio for over four years.